DarioHealth Prices $23.5 Million Registered Direct Offering at $6.80 Per Share
On July 22, 2026, DarioHealth agreed to sell 2,437,060 common shares and pre-funded warrants for 1,017,499 shares to institutional investors in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of about $23.5 million before fees. The sale adds new shares outstanding, and the company has agreed not to issue more shares for 30 days after closing, which is expected on or about July 23, 2026, apart from its existing at-the-market facility.
Key points
- Shares priced at $6.80 each; pre-funded warrants priced at $6.7999 each, covering 1,017,499 shares
- Gross proceeds of about $23.5 million; placement agent cash fee of 6.0%, with a 1.0% fee on certain investor proceeds, plus expenses up to $60,000
- Board member Dennis Matheis agreed to buy 14,430 shares at $6.93 per share
- Company may not issue further shares for 30 days after closing, expected on or about July 23, 2026, except under its existing at-the-market facility and Form S-8 plans
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.